ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 27.3% during mid-day trading on Friday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,056,761 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 8,429,979 shares. The stock had previously closed at GBX 9.90 ($0.13).
ImmuPharma Price Performance
The stock has a market cap of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The company has a 50 day simple moving average of GBX 7.70 and a 200-day simple moving average of GBX 4.29.
ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.
About ImmuPharma
(
Get Free Report)
ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.
While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
